Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14866687 | 0.81 | L3MBTL1 (0.46) | MEN1KMT2ALTA4HALDH1A1L3MBTL1 | |
| SCHEMBL6228744 | 0.77 | ACHE (0.42) | ACHEPTGS2BCHEMEN1KMT2A | |
| SCHEMBL14845923 | 0.76 | CXCR4 (0.46) | MEN1KMT2ALTA4HALDH1A1CXCR4 | |
| SCHEMBL5591066 | 0.72 | BCHE (0.47) | ACHEPTGS2BCHEMEN1KMT2A | |
| SCHEMBL12988223 | 0.72 | SMN1; SMN2 (0.41) | ACHEPTGS2BCHEMEN1KMT2A | |
| SCHEMBL29609887 | 0.72 | CXCR4 (0.54) | MEN1KMT2ALTA4HCXCR4 | |
| SCHEMBL2047868 | 0.72 | ACHE (0.44) | ACHEPTGS2BCHEMEN1KMT2A | |
| SCHEMBL8345386 | 0.70 | L3MBTL1 (0.41) | ACHEPTGS2BCHEMEN1KMT2A | |
| SCHEMBL4923116 | 0.69 | CYP2C19 (0.58) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11862227 | 0.69 | CXCR4 (0.51) | MEN1KMT2ALTA4HCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853217-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130096139-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096139-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, CHEK2 | ACHE 3980/4885PTGS2 2996/4885BCHE 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.